Traders Get Bullish on Shares of Curis, Shares Up 6.8% (CRIS)
Comtex SmarTrend(R) - Mon Dec 22, 11:35AM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 6.8% to $1.25 on 1.0x average daily volume. Thus far today, Curis has traded 382,000 shares, vs. average volume of 381,000 shares per day. The stock has outperformed the Dow (6.8% to the Dow's 0.5%) and outperformed the S&P 500 (6.8% to the S&P's 0.0%) during today's trading.
CRIS: 1.29 (+0.04)
Curis Announces Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients With Advanced/ Relapsed Solid Tumors
GlobeNewswire - Thu Dec 18, 6:06AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that the first patient has initiated treatment with CUDC-907 in a Phase 1 clinical trial in patients with advanced or relapsed solid tumors, including hormone receptor positive (HR+)/ HER2-negative breast cancer or midline carcinoma with certain NUT gene rearrangements. CUDC-907 is an oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes that is currently under investigation in the first-in-human Phase 1 clinical study in patients with relapsed or refractory lymphomas and multiple myeloma.
CRIS: 1.29 (+0.04)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Curis to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Nov 26, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that the Company will present at the following upcoming conferences:
CRIS: 1.29 (+0.04)
Hot Stock: Curis, Shares Gain 5.9% (CRIS)
Comtex SmarTrend(R) - Tue Nov 25, 11:35AM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 5.9% to $1.44 on 1.0x average daily volume. Curis has traded 289,000 shares thus far today, vs. average volume of 278,000 shares per day. The stock has outperformed the Dow (5.9% to the Dow's 0.1%) and outperformed the S&P 500 (5.9% to the S&P's -0.1%) during today's trading.
CRIS: 1.29 (+0.04)
Curis to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that the Company will present at the Stifel 2014 Healthcare Conference at 2:25 p.m. EST on Wednesday, November 19, 2014 in New York City.
CRIS: 1.29 (+0.04)
Titan Pharmaceuticals Appoints Two New Board Members
Marketwired - Tue Nov 11, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has appointed life sciences industry veterans Joseph A. Akers and James McNab Jr. to its board of directors. Mr. Akers, a former Bayer HealthCare executive, and Mr. McNab, chairman and co-founder of Curis, Inc., together bring extensive product development, commercialization, finance and corporate governance experience to Titan.
CRIS: 1.29 (+0.04)
Curis' (CRIS) CEO, Ali Fattaey on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 12:58PM CST
CRIS: 1.29 (+0.04)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 3.02 (-0.05), CRIS: 1.29 (+0.04), IMMU: 4.41 (+0.13), PCYC: 121.84 (+1.15), ONCY: 0.49 (unch), PFE: 31.42 (-0.03), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), JNJ: 104.59 (+0.31), SNTA: 2.63 (+0.02), NVS: 93.91 (+0.66), XLRN: 38.80 (+0.80), ARRY: 4.64 (+0.07), CELGZ: 3.34 (-0.01), EXEL: 1.29 (-0.01)
Curis lowers revenues 75% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:29AM CST
CRIS: 1.29 (+0.04)
Curis (CRIS) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 7:55AM CST
CRIS: 1.29 (+0.04)
Curis misses Street 3Q forecasts
Automated Insights - Mon Nov 10, 6:15AM CST
LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Monday reported a third-quarter loss of $5.6 million.
CRIS: 1.29 (+0.04)
Curis misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:12AM CST
CRIS: 1.29 (+0.04)
Curis Reports Third Quarter 2014 Financial Results and Pipeline Update
GlobeNewswire - Mon Nov 10, 6:07AM CST
-- Curis Provides Summary From Dose Escalation Stage of CUDC-907 Phase 1 Study Supporting Ongoing Expansion in DLBCL Patients -
CRIS: 1.29 (+0.04)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:30PM CST
BID: 43.31 (+0.01), CRIS: 1.29 (+0.04), KWK: 0.20 (+0.01), ARQL: 1.15 (+0.01), CACQ: 9.96 (+0.12), RIG: 18.77 (-0.37), TRQ: 2.91 (unch), MPAA: 33.40 (+0.52), RSPP: 26.14 (-0.09), DF: 18.96 (-0.01), ENTR: 2.26 (-0.06), TA: 12.21 (+0.01), DDD: 30.54 (-0.64), RYN: 28.31 (unch), GAS: 54.01 (+1.29), CMCM: 15.00 (-0.02), LIOX: 5.82 (+0.05), WWAV: 35.98 (+0.72), ZINC: 15.17 (+0.29), GTXI: 0.77 (-0.05), GOGO: 16.48 (+0.05), RIGP: 14.91 (-0.42), EVEP: 21.87 (-0.94), SNSS: 2.48 (-0.03), MGIC: 6.45 (-0.01)
Curis reports November 10
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 10:22AM CST
CRIS: 1.29 (+0.04)
Curis to Release Third Quarter 2014 Financial Results and Hold Conference Call on November 10, 2014
GlobeNewswire - Mon Nov 03, 6:01AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that the Company will release its third quarter financial results on Monday, November 10, 2014, before the market opens. The Company's management will also host a conference call on the same day at 9:00 A.M. EST to provide an overview of its proprietary clinical development programs, including CUDC-907 and CUDC-427, as well as its partnered programs, including Erivedge(R) (vismodegib) and Debio 0932. The Company's management will also review its financial results as of and for the three- and nine-month periods ended September 30, 2014.
CRIS: 1.29 (+0.04)
Curis Announces Allowance of U.S. Patent Covering Compounds Targeting HDAC and PI3K Activities in a Single Molecule
GlobeNewswire - Tue Oct 28, 6:15AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced the receipt of a Notice of Allowance of a U.S. patent that covers a broad genus of compounds that target histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) activities in a single chemical structure including CUDC-907, Curis' oral, dual HDAC and PI3K small molecule inhibitor that is currently being studied in Phase 1 clinical trials. This patent, along with prior patents issued to Curis, further strengthens the Company's intellectual property portfolio of compounds including CUDC-907 that inhibit HDAC and PI3K enzymes in a single small molecule for the treatment of certain human diseases.
CRIS: 1.29 (+0.04)
Curis to Present at the 13th Annual BIO Investor Forum
GlobeNewswire - Fri Oct 03, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that the Company will present at the 13 Annual BIO Investor Forum at 8:00 am PDT on Tuesday, October 7, 2014 in San Francisco, CA.
CRIS: 1.29 (+0.04)